However, when stratified by tumor stage, high SLAMF3 expression was significantly correlated with reduced OS in stage 3+4 CRC patients (n = 564) (P < 0.05; Figure 9K), but not in stage 1+2 patients (n = 493) (Figure 9J). Here, LY9 is linked to colorectal carcinoma.